Immunogenicity testing of a recombinant N1 vaccine candidate in vivo

Female 6-8 week old BALB/c mice were vaccinated in a prime/boost regimen with 3ug of recombinant N1-MPP protein. The protein was administered intramuscularly either alone or in combination with different adjuvants to enhance the immune response. Furthermore, N1-MPP was used to supplement different seasonal available QIVs and was then either administered in a mixture containing both N1 and QIV or administered in different legs, QIV in the left leg and N1 at the same time in the right leg. Afterward, the mice were challenged with 25x LD50 of A/Singapore/GP1908/2015 (H1N1) virus, and weight loss and survival were monitored over 2 weeks. Afterward, serological analysis of the serum obtained after 1st and 2nd vaccination was conducted.